Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events
Share Article
The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, is pleased to announce the publication of a clinical practice guideline for the management of cell therapy adverse events. Immune effector cell therapies include the three U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cell products for treatment of blood-based cancers.
“This is the tenth manuscript published in SITC’s Cancer Immunotherapy Guidelines series, a critically important effort to educate physicians and other health care providers, and improve outcomes for cancer patients receiving FDA-approved immunotherapies, said SITC President Mario Sznol, MD.